10-Q: Corcept Therapeutics Reports Q1 2025 Results: Revenue Up, Relacorilant NDA Accepted

Corcept Therapeutics' Q1 2025 revenue increased, driven by higher sales volume, while the FDA accepted the NDA for relacorilant, a potential treatment for hypercortisolism.

Summary

• Corcept Therapeutics Incorporated reported its financial results for the quarter ended March 31, 2025.
• Net product revenue increased to $157.2 million, compared to $146.8 million for the same period in 2024.
• The increase in revenue was primarily driven by a 23.5% increase in sales volume, partially offset by a 13.3% decrease in average price due to higher sales volume from the authorized generic version of Korlym.
• Research and development expenses increased to $60.7 million, compared to $58.5 million in the prior year.
• Selling, general, and administrative expenses rose to $90.7 million, compared to $56.3 million in the same period of 2024.
• The FDA accepted the New Drug Application (NDA) for relacorilant with a target action date of December 30, 2025.
• The company repurchased 0.5 million shares of its common stock for $27.4 million under the stock repurchase program.
• The company initiated the MOMENTUM trial to establish the prevalence of endogenous hypercortisolism in patients with resistant hypertension, with a planned enrollment of 1,000 patients.
• The company initiated a Phase 2 trial (BELLA) of relacorilant plus nab-paclitaxel and bevacizumab evaluating efficacy and safety in patients with platinum-resistant ovarian cancer, with a planned enrollment of 90 patients.
• The company had cash, cash equivalents, and marketable securities of $570.8 million as of March 31, 2025.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with revenue growth and regulatory progress, but also acknowledges challenges such as generic competition and ongoing litigation.

Positives

• Net product revenue increased year-over-year, indicating continued demand for the company's products.
• FDA acceptance of the relacorilant NDA represents a significant milestone in the development of a potential new treatment for hypercortisolism.
• The initiation of new clinical trials (MOMENTUM and BELLA) demonstrates the company's commitment to expanding its pipeline and addressing unmet medical needs.
• The company maintains a strong cash position, providing financial flexibility for ongoing operations and strategic initiatives.
• The company is actively returning capital to shareholders through its stock repurchase program.

Negatives

• The average selling price decreased due to the introduction of a generic version of Korlym, which could impact future revenue growth.
• Increased selling, general, and administrative expenses may indicate higher costs associated with commercialization efforts.
• The ongoing legal proceedings, including the antitrust litigation and shareholder derivative complaints, could result in significant expenses and management distraction.

Risks

• The availability of generic versions of Korlym could adversely affect the company's business, results of operations, and financial position.
• The company's efforts to discover, develop, and commercialize its product candidates may not succeed, and clinical drug development is lengthy, expensive, and often unsuccessful.
• The company may not be able to secure, maintain, or effectively assert patent protection for its proprietary, selective cortisol modulators.
• The price of the company's common stock fluctuates widely and is likely to continue to do so.
• The company faces unprecedented political, legal, governmental, regulatory, and economic uncertainty and risks that may adversely affect its business.

Future Outlook

The company expects to fund its operations and planned research and development activities over the next 12 months and beyond without needing to raise additional funds, although it may choose to raise additional funds for other reasons. The company expects research and development expense to be higher in 2025 than in 2024 as its clinical programs advance and it initiates new clinical trials. The company expects selling, general and administrative expense to be higher in 2025 than in 2024 due to increased commercial and administrative activities to support increased sales and marketing efforts.

Management Comments

• Our policy is that no patient with hypercortisolism will be denied access to our Products for financial reasons.
• We are developing our proprietary, selective cortisol modulator, relacorilant, as a treatment for patients with hypercortisolism.
• We will vigorously enforce our intellectual property rights relating to Korlym but cannot predict the outcome of these matters.

Industry Context

Corcept Therapeutics operates in the biopharmaceutical industry, focusing on the discovery, development, and commercialization of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders. The company's primary focus is on modulating the effects of the hormone cortisol. The company faces competition from other pharmaceutical companies that offer different medications to treat patients with hypercortisolism, including Recordati-S.p.A. and Xeris.

Comparison to Industry Standards

• Corcept's revenue growth of approximately 7% year-over-year is within the range of growth seen by other specialty pharmaceutical companies.
• The company's R&D spending as a percentage of revenue is comparable to other companies in the biopharmaceutical industry that are focused on clinical development.
• The company's cash position is strong compared to other companies of similar size in the biopharmaceutical industry.
• Corcept's stock repurchase program is a common practice among publicly traded companies with strong cash flow.

Legal Proceedings

• Corcept is involved in patent litigation with Teva Pharmaceuticals regarding generic versions of Korlym.
• Corcept is involved in antitrust litigation with Teva Pharmaceuticals and Aetna Inc.
• Corcept is involved in shareholder derivative litigation.
• Corcept received a records subpoena from the United States Attorneys Office for the District of New Jersey (the NJ USAO) seeking information relating to the sale and promotion of Korlym.

Stakeholder Impact

• Shareholders: The company's financial performance and strategic initiatives impact shareholder value.
• Patients: The company's products and product candidates aim to improve the lives of patients with severe endocrinologic, oncologic, metabolic, and neurologic disorders.
• Employees: The company's growth and success provide opportunities for employees.
• Customers: The company's products are sold to physicians and patients through specialty pharmacies and distributors.
• Suppliers: The company relies on suppliers for the manufacturing and distribution of its products.

Next Steps

• Continue commercialization efforts for Korlym and the authorized generic version.
• Advance the clinical development of relacorilant and other product candidates.
• Prepare for the potential commercial launch of relacorilant pending FDA approval.
• Monitor and respond to ongoing legal proceedings.
• Continue to evaluate and manage the impact of the Inflation Reduction Act of 2022.

Key Dates

Keywords

relacorilant, hypercortisolism, Korlym, clinical trials, revenue, FDA, stock repurchase, oncology, mifepristone, generic